Welcome to our dedicated page for Utah Med Prods SEC filings (Ticker: UTMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Utah Medical Products Inc. filings document formal disclosures for a Utah-incorporated medical device manufacturer whose common stock trades on Nasdaq under the symbol UTMD. Recent Form 8-K reports furnish quarterly and annual financial information, including sales, margins, earnings measures and exhibits containing the company's financial-performance releases.
The filing record also covers governance and capital-return matters. Definitive proxy materials describe director elections, auditor ratification, advisory executive-compensation votes and annual meeting procedures, while 8-K reports record stockholder voting results, board appointments, committee service, director compensation arrangements and quarterly dividend announcements.
UTAH MEDICAL PRODUCTS INC principal financial officer Brian Koopman reported a bona fide gift transfer of 50 shares of Common Stock. The gifted shares were valued at $66.27 per share for reporting purposes. Following the gift, he directly holds 782 shares of the company’s stock.
Brandes Investment Partners amended a Schedule 13G to report beneficial ownership in Utah Medical Products, Inc. The filing states Brandes beneficially owns 449,680 shares, representing 14.12% of the class, with 412,007 shares reflecting shared voting power.
The disclosure lists CUSIP 917488108 and the reporting person as Brandes Investment Partners, L.P. The amendment is signed by Glenn Carlson as Executive Director.
Utah Medical Products reported lower first-quarter 2026 results, with solid margins but declines in sales and earnings versus a strong prior year. Net sales were $8,722k, down 10.2% from $9,710k, mainly due to the loss of a major China blood pressure monitoring distributor and an OEM customer.
Net income was $2,604k versus $3,041k, a 14.4% decrease, and diluted EPS fell to $0.82 from $0.92, helped somewhat by share repurchases that reduced the share count. Despite lower profit, gross margin improved to 60.6% from 57.0% on a more favorable product mix and a standard cost adjustment.
The company generated $3,109k of operating cash flow (down from $4,464k), ended the quarter with $87,406k in cash and investments, no debt, and stockholders’ equity of $120,373k. Utah Medical Products repurchased 2,196 shares for $129k and paid $989k in dividends while maintaining a very high current ratio and emphasizing continued buybacks and dividends as capital allocation priorities.
Utah Medical Products, Inc. reported the results of its annual stockholder meeting held on May 1, 2026. Stockholders elected Ernst G. Hoyer and James H. Beeson as directors, with Beeson receiving 1,708,941 votes for and Hoyer 1,330,333 votes for, alongside broker non-votes on each proposal.
Stockholders also ratified the selection of Haynie & Co. as the company’s independent public accounting firm for the year ended December 31, 2026, with 2,753,278 votes for. On an advisory basis, stockholders approved the compensation of the company’s named executive officers, with 2,354,919 votes for. The company plans to continue holding annual advisory votes on executive compensation until at least the next required vote on the frequency of these votes.
Utah Medical Products reported Q1 2026 results with net sales of $8.7 million, down 10.2% from Q1 2025. Net income declined 14.4% to $2.6 million, while earnings per share fell 11.0% to $0.818. Despite lower revenue, the company’s gross margin improved to 60.6% from 57.0%, reflecting a more profitable product mix and cost adjustments.
Operating income decreased 18.7% to $2.6 million as higher general and administrative costs, including litigation and health care expenses, weighed on results. The balance sheet remained debt-free, with cash and investments rising to $87.4 million and stockholders’ equity increasing to $120.4 million.
Utah Medical Products, Inc. (UTMD) is asking stockholders to vote at the May 1, 2026 annual meeting on three items: electing two directors to terms expiring at the 2029 meeting, ratifying Haynie & Company as independent auditor for 2026, and an advisory vote approving the executive compensation program.
Only holders of 3,185,025 common shares outstanding as of March 2, 2026 may vote, with one vote per share. Directors and executive officers held 228,616 shares directly at the end of 2025, about 7% of the stock. In 2025 the CEO earned total pay of $341,709, while the median employee earned about $43,500, a pay ratio of roughly 1:8. The company highlights its profit-sharing bonus plan, nonqualified stock option plan, retirement contributions and group benefits as key elements of compensation, and discloses an executive clawback policy and a change-in-control agreement for the CEO.
Utah Medical Products reported 2025 revenue of $38.5 million, down 5.8% from 2024, as several key customers reduced orders or exited. Net income fell 18.7% to $11.3 million, and GAAP EPS declined 12.1% to $3.483, reflecting lower sales and higher operating costs.
The sharpest hit came from OEM customer PendoTECH and a Chinese distributor that canceled part of its 2025 order and left a receivable that was written off. Filshie device revenue slipped overall, though U.S. hospital sales grew. Even with these pressures, UTMD maintained gross margin above 57% and ended the year with $85.8 million in cash after paying dividends and repurchasing about 4.5% of its shares.
Utah Medical Products Inc received Amendment No. 2 to a Schedule 13G/A from The Vanguard Group stating that, following an internal realignment effective January 12, 2026, The Vanguard Group reports 0 shares (0%) beneficially owned of the company’s common stock. The filing is signed by Ashley Grim, Head of Global Fund Administration on March 27, 2026, and cites SEC Release No. 34-39538 as the basis for disaggregated reporting by Vanguard subsidiaries.
Utah Medical Products, Inc. furnished an update on its business by providing financial information for the three and twelve months ended December 31, 2025, in a press release dated January 29, 2026. The press release, attached as Exhibit 99.1, also contains forward-looking statements about 2025 and beyond.
The company submitted this information under a current report, stating that the material is being furnished rather than filed, so it is not subject to certain Exchange Act liabilities and is not automatically incorporated into other securities law filings.
Utah Medical Products Inc. director Kevin Timken reported an initial beneficial ownership position that includes a stock option to buy 10,000 shares of the company’s common stock. The option has an exercise price of $58.10 per share, becomes exercisable on 10/01/2026, and expires on 10/31/2035.
The option vests 25% on 10/01/2026, with an additional 6.25% vesting on 01/01/2027 and on the first day of each calendar quarter thereafter, becoming fully exercisable on 10/01/2029. This filing reflects his status as a director and provides transparency into his equity-based compensation.